| Brenda K Redmon, PA | |
|
3550 Parkwood Blvd, Suite 600, Frisco, TX 75034-1903 | |
| (972) 377-8800 | |
| (972) 377-8808 |
| Full Name | Brenda K Redmon |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Location | 3550 Parkwood Blvd, Frisco, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043480270 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | PA05578 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brenda K Redmon, PA 3550 Parkwood Blvd, Suite 600, Frisco, TX 75034-1903 Ph: (972) 377-8800 | Brenda K Redmon, PA 3550 Parkwood Blvd, Suite 600, Frisco, TX 75034-1903 Ph: (972) 377-8800 |
News Archive
A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary hepatocellular cancer including those with disease that has spread outside the liver, according to the results of a prospective clinical study presented today at the 46th American Society of Clinical Oncology conference.
Scientists at The Wistar Institute have unveiled part of the protein complex that protects telomeres-;the ends of our chromosomes. The study, published online in Nature Communications, explains how a group of genetic mutations associated with this protein complex contributes to various cancers.
A small, retrospective study determined that percutaneous coronary intervention (PCI) was safe in patients with significant coronary artery disease (CAD) who were referred for liver transplantation. Larger studies are needed to determine the effectiveness of angioplasty in patients with end-stage liver disease (ESLD). Details of the study are available in the July issue of Liver Transplantation, published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Women could benefit greatly from the Affordable Care Act's mandate for contraceptive coverage, according to Penn State College of Medicine researchers.
› Verified 9 days ago
Mrs. Ann Kathryn Smith, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 4401 Coit Rd Ste 411, Frisco, TX 75035 Phone: 972-731-7654 Fax: 972-731-6226 | |
Jonathon Thai Ngo, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 255 Lebanon Road, Unit 132, Frisco, TX 75036 Phone: 469-310-4400 | |
Mr. Michael Lee Burns, OPA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 4461 Coit Rd, Ste 101, Frisco, TX 75035 Phone: 972-335-8455 Fax: 972-335-7560 | |
Daniel Archer, Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 4401 Coit Rd Ste 203, Frisco, TX 75035 Phone: 469-800-7070 | |
Mrs. Christi Kay Kobald, PA-C, MMS Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 4461 Coit Rd, Suite 405, Frisco, TX 75035 Phone: 972-377-9200 Fax: 972-377-9300 | |
Adrianne Bailey, PA Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 7000 Parkwood Blvd Ste F100, Frisco, TX 75034 Phone: 214-494-4424 Fax: 214-494-4423 |